ArticleCellular & molecular immunology2021

Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.

Yan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.